Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing treatments for central nervous system diseases, provided clinical updates for its investigational programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at their recent R&D Day. The company discussed the results of comprehensive data analysis for TSHA-120, addressing feedback from the U.S..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress. The RaDaR natural history study indicates that patients with autosomal recessive COL4A4 mutations have the severest form of the disease, with a more rapid progression to kidney f..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 22.
  • textsms